6657 Stock Overview
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Energenesis Biomedical CO.,LTD. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$54.40 |
52 Week High | NT$99.50 |
52 Week Low | NT$51.50 |
Beta | 0.54 |
1 Month Change | -6.69% |
3 Month Change | -12.82% |
1 Year Change | -13.79% |
3 Year Change | -17.20% |
5 Year Change | 25.78% |
Change since IPO | 75.48% |
Recent News & Updates
Shareholder Returns
6657 | TW Biotechs | TW Market | |
---|---|---|---|
7D | -0.5% | -1.1% | -0.6% |
1Y | -13.8% | -21.5% | 29.2% |
Return vs Industry: 6657 exceeded the TW Biotechs industry which returned -21.5% over the past year.
Return vs Market: 6657 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
6657 volatility | |
---|---|
6657 Average Weekly Movement | 5.2% |
Biotechs Industry Average Movement | 4.8% |
Market Average Movement | 4.7% |
10% most volatile stocks in TW Market | 8.7% |
10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6657 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6657's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 35 | Han-min Chen | www.energenesis-biomedical.com |
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control.
Energenesis Biomedical CO.,LTD. Fundamentals Summary
6657 fundamental statistics | |
---|---|
Market cap | NT$4.14b |
Earnings (TTM) | -NT$260.38m |
Revenue (TTM) | NT$7.16m |
578.1x
P/S Ratio-15.9x
P/E RatioIs 6657 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6657 income statement (TTM) | |
---|---|
Revenue | NT$7.16m |
Cost of Revenue | NT$1.93m |
Gross Profit | NT$5.23m |
Other Expenses | NT$265.61m |
Earnings | -NT$260.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.42 |
Gross Margin | 73.02% |
Net Profit Margin | -3,637.64% |
Debt/Equity Ratio | 0% |
How did 6657 perform over the long term?
See historical performance and comparison